HeartFlow targets $218M–$222M in 2026 revenue and accelerates PCI Navigator launch while expanding plaque coverage

Earnings Call Insights: HeartFlow, Inc. (HTFL) Q4 2025

MANAGEMENT VIEW

* CEO John Farquhar opened the call highlighting "outstanding financial performance driven by the sustained adoption of our HeartFlow platform and strong execution across our commercial, innovation and clinical initiatives." He stated total fourth quarter revenue was $49.1 million, representing more than 40% year-over-year growth, with global cases up nearly 53% and non-GAAP gross margin reaching nearly 80%.
* Farquhar announced full year 2026 revenue guidance in the range of $218 million to $222 million, expecting approximately 24% to 26% year-over-year growth. The company anticipates full year 2026 plaque revenue of $15 million to $17 million, supported by reimbursement progress and installed base expansion.
* The company is targeting full year 2026 non-GAAP gross margin of 80% to 81%, with an increased midterm target of 85%, citing "continued volume leverage, AI-driven efficiencies and the increased contribution of higher-margin plaque revenue."
* Farquhar described record installed base expansion, with 340 new U.S. accounts added in 2025, closing at 1,465 accounts. Plaque account additions reached 489 accounts by year-end, and the technology is now covered by Aetna, UnitedHealthcare, Cigna, and Humana, representing approximately 75% of U.S. covered lives.
* HeartFlow is advancing its innovation pipeline by launching PCI Navigator, an AI-driven planning tool for interventional cardiologists, ahead of schedule in April 2026. The company also unveiled HeartFlow autonomous processing—a major AI-driven efficiency initiative to transition case processing into a highly automated model.
* The company is expanding into the high-risk asymptomatic population, estimating this U.S. market at $6 billion. HeartFlow plans to initiate three randomized controlled trials in targeted subpopulations over the next 12 months.
* CFO Vikram Verghese stated, "Total revenue for the fourth quarter was $49.1 million, up 40%. U.S. revenue grew to $44.8 million, up 41% OUS and other revenue grew to $4.3 million. Total global revenue cases for the quarter were 57,776, representing 53% growth."

OUTLOOK

* HeartFlow initiated full year 2026 revenue guidance of $218 million to $222 million, with plaque revenues expected to contribute $15 million to $17 million, weighted toward the second half as clinical experience builds.
* Non-GAAP gross margin guidance for 2026 is 80% to 81%, with a midterm target of 85%. Drivers include volume efficiencies, AI-driven improvements, and high-margin plaque revenue.
* The company expects plaque revenue to become more significant in the back half of the year and is not factoring in utilization tailwinds from the PCI Navigator launch into current guidance.

FINANCIAL RESULTS

* Fourth quarter revenue was $49.1 million, with U.S. revenue at $44.8 million and international/other revenue at $4.3 million.
* Global revenue cases for Q4 were 57,776. Non-GAAP gross margin reached nearly 80%, up from 75.3% in Q4 2024.
* Fourth quarter SG&A expenses were $34.6 million, and R&D expenses were $17.1 million. Operating loss was $12.5 million, with non-GAAP net loss at $9.8 million or a loss of $0.12 per share. GAAP net loss was $24.4 million or a loss of $0.29 per share, including a $9.3 million noncash charge from warrant remeasurement. Cash, cash equivalents, and investments at quarter-end were $280.2 million.

Q&A

* Robert Marcus, JPMorgan: Asked about confidence in 2026 guidance and plaque assumptions. Farquhar responded, "I've never been more confident in this business and what we're setting up to deliver here... there's fundamental demand out there, and I could not be happier with our team's track record of execution."
* Marcus followed up on competitive moats with AI. Farquhar stated, "I would characterize our moat as highly defensible... an AI model is only as good as the training set and the data that, that model is trained on. And we have... the world's largest proprietary CT database of annotated CT images, okay? We've got over 160 million images."
* William Plovanic, Canaccord Genuity: Inquired about recent product innovations and PCI Navigator. Farquhar described the launch timeline and impact, while Verghese added, "our current forecast really does not assume any incremental upside from PCI Navigator."
* Matthew O'Brien, Piper Sandler: Asked about plaque pricing. Verghese explained "we have underwritten modest ASP upside in the '26 plan and then more meaningful step-ups in future years."
* O'Brien also questioned case numbers per site and guidance conservatism. Verghese said, "we did outperform despite the heavy onboard number. We were about 15% higher on a cases per site basis in 4Q '25 relative to where consensus came at."
* Nathan Treybeck (for Larry Biegelsen), Wells Fargo: Asked about plaque utilization trends. Farquhar stated, "the total applicability for plaque is 60% of all patients, okay? We're nowhere near 60% right now because we've just kind of got out the gates here."
* John (for Rick Wise), Stifel: Asked about CCTA adoption and competition. Farquhar noted, "CCTA... is around 10% to 12%, I think, penetrated relative to the whole standard of care. So there's lots of ways to go before we get there."

SENTIMENT ANALYSIS

* Analysts pressed for clarity on the pace of plaque adoption, competitive differentiation, and guidance assumptions, demonstrating a slightly positive to neutral sentiment as they acknowledged momentum but sought reassurance on execution and market ramp.
* Management maintained a confident and optimistic tone, with Farquhar stating, "I've never been more confident in this business..." and consistently emphasizing execution strength, pipeline progress, and defensible moats. The tone during prepared remarks was assertive, while Q&A responses blended confidence with pragmatic caution regarding guidance and adoption curves.
* Compared to the previous quarter, analyst tone was incrementally more positive, reflecting greater acceptance of HeartFlow’s accelerating adoption and innovation pipeline. Management’s tone remained consistently confident but more assertive in outlining upside optionality and execution milestones.

QUARTER-OVER-QUARTER COMPARISON

* Guidance for 2026 has moved from a 2025 revenue range of $173 million–$173.5 million to a new target of $218 million–$222 million, with the addition of plaque revenue forecasts.
* Midterm non-GAAP gross margin target increased from 80% to 85%, reflecting a more aggressive outlook on AI-driven efficiencies and plaque contribution.
* Strategic focus continues on commercial adoption, but the addition of high-risk asymptomatic population trials and the earlier-than-expected PCI Navigator launch signal a more expansive growth agenda.
* Analyst focus shifted from initial post-IPO adoption and coverage milestones to the pace of plaque ramp, competitive AI positioning, and new innovation impacts.
* Management’s confidence has grown more explicit, with repeated emphasis on high-conviction guidance and upside potential, compared to a more measured tone in the prior quarter.

RISKS AND CONCERNS

* Management acknowledged that meaningful plaque revenue is weighted toward the back half of 2026, dependent on clinician adoption and outcomes data.
* Farquhar noted that plaque ramp is "not going to be a light switch moment" and requires ongoing physician education and clinical experience.
* Analysts questioned if current FFRCT revenue guidance was conservative given strong recent performance, and whether PCI Navigator’s launch could drive incremental upside.
* Competitive risks were addressed by emphasizing proprietary data and clinical evidence as defensible moats.

FINAL TAKEAWAY

Management maintains high conviction in HeartFlow’s growth prospects, underpinned by record platform adoption, robust guidance for 2026, and a clear strategy to drive both commercial and clinical expansion. With early momentum in plaque adoption, new AI-driven product launches, and a significant increase in covered lives, HeartFlow aims to accelerate both top line growth and margin improvement while broadening its addressable market. The company’s confidence is rooted in strong execution, continued innovation, and a reinforced competitive position supported by expanding clinical evidence and payer coverage.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/htfl/earnings/transcripts]

MORE ON HEARTFLOW, INC.

* HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4883858-heartflow-inc-htfl-q4-2025-earnings-call-transcript]
* HeartFlow, Inc. (HTFL) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript [https://seekingalpha.com/article/4877844-heartflow-inc-htfl-presents-at-morgan-stanley-technology-media-and-telecom-conference-2026]
* HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript [https://seekingalpha.com/article/4859422-heartflow-inc-htfl-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript]
* Historical earnings data for HeartFlow, Inc. [https://seekingalpha.com/symbol/HTFL/earnings]
* Financial information for HeartFlow, Inc. [https://seekingalpha.com/symbol/HTFL/income-statement]